SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-17-004968
Filing Date
2017-05-10
Accepted
2017-05-10 16:21:55
Documents
64
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm 10-Q 568004
2 ex31-1.htm EX-31.1 17790
3 ex31-2.htm EX-31.2 17801
4 ex32-1.htm EX-32.1 9499
  Complete submission text file 0001493152-17-004968.txt   3492002

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE immy-20170331.xml EX-101.INS 561200
6 XBRL SCHEMA FILE immy-20170331.xsd EX-101.SCH 50446
7 XBRL CALCULATION FILE immy-20170331_cal.xml EX-101.CAL 73846
8 XBRL DEFINITION FILE immy-20170331_def.xml EX-101.DEF 170670
9 XBRL LABEL FILE immy-20170331_lab.xml EX-101.LAB 349028
10 XBRL PRESENTATION FILE immy-20170331_pre.xml EX-101.PRE 257274
Mailing Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130
Business Address 12264 EL CAMINO REAL SUITE 350 SAN DIEGO CA 92130 858-704-4042
Imprimis Pharmaceuticals, Inc. (Filer) CIK: 0001360214 (see all company filings)

IRS No.: 450567010 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35814 | Film No.: 17830582
SIC: 2834 Pharmaceutical Preparations